Navigation Links
Landmark trial to evaluate cardioprotective properties of insulin
Date:11/9/2007

BUFFALO, N.Y. -- The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.

Approximately 600 patients at 90 centers in the U.S. and Latin America will be recruited to participate in the two-year INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial. Patients in the trial, which is funded by sanofi-aventis, will be treated with two forms of insulin -- insulin glargine and insulin glulisine.

Kaleida Healths Diabetes-Endocrine Center of Western New York, which Dandona directs, will be one of the vanguard centers. The centers research facility, located in UBs New York State Center of Excellence in Bioinformatics and Life Sciences, will serve as the core laboratory.

Richard W. Nesto, M.D., associate professor at Harvard Medical School and chair of cardiovascular medicine at Lahey Clinic Medical Center in Burlington, Mass., will be co-principal investigator, directing the trials cardiovascular aspects.

The trial is based on a pilot study conducted by the diabetes center, which documented that insulin, used to treat and control type 1 and type 2 diabetes, was also cardioprotective.

This pilot study, published in the journal Circulation in 2004, was conducted in 32 patients receiving low-dose insulin. C-reactive protein (CRP) and serum amyloid A (SAA), two critical markers of inflammation, were reduced by 40 percent and 50 percent, respectively, during the 48 hours following a heart attack. Concentrations of three additional inflammatory factors also were significantly lower in those who received insulin, compared to those who did not.

The markers of myocardial damage that we measured were reduced significantly, said Dandona.
'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. New Heart Pump Shows Promise in Trial
9. Trial to Test Gene Therapy for Angina in Women
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
(Date:7/28/2014)... Maureen Salamon HealthDay Reporter ... Infants and children who are at risk of contracting ... against the infection, according to updated recommendations from the ... And routine vaccinations for the potentially deadly infection should ... of Pediatrics says. In its first statement on ...
(Date:7/28/2014)... Endurance runners are far more likely to die of ... a new study. The researchers pointed out ... are actually 10 times more likely to develop severe ... death of a young and apparently healthy person due ... often gets a lot more media attention. "This ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... recipe app for iOS, App is available on iTunes for ... first of its kind, Audio Chef allows you to listen ... gourmet cuisine the easy way: simply get out the ingredients ... no need to measure or prepare ingredients ahead of time, ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
Breaking Medicine News(10 mins):Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Harry Leider, M.D., MBA, FACPE, Ameritox,s Senior Vice President ... Chairman of the Board for the American College of Physician ... physician leaders. , , Dr. Leider became an ... faculty member within the College for 13 years teaching courses ...
... low cellular level of a tiny fragment of RNA ... mouse models of the disease, according to researchers at ... of this so-called microRNA, which is also associated with ... the likelihood of metastasis (which accounts for 90% of ...
... Morning Tuesday, June 16, 2009 at 9:00 a.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... equity of Symphony Allegro. The purchase of Symphony Allegro, ... close in Q3 2009. , , Alexza and Symphony ...
... AMDL Inc. (NYSE Alternext US: ADL), a US-based ... closing of a private placement offering of "units" consisting of 12% ... for the offering is Cantone Research Inc. , , In ... 12% Series 2 convertible notes at par value and completed the ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... Barak Obama speaks to the American Medical Association (AMA) today ... including physicians from coast to coast, is listening. ... will not support a public health insurance, option. Since the ... an anti-public insurance stance, the AMA is fostering the notion ...
Cached Medicine News:Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:RNA snippet suppresses spread of aggressive breast cancer 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes 2Health News:AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes 3Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Indiana U. expert says nation's physicians support national health insurance 2
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... Atrium Medical Corporation today announced the publication ... Vascular Surgery.  COBEST ( Covered Versus Balloon Expandable ... multi center, randomized, controlled clinical trial that has ... technology is superior to traditional bare metal stents ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 3
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
... wall .90 mm (20 g) ... 6 mm in length. Cannula ... sclerotomy. 3201 has 16 cm ... tubing to allow injection of ...
Medicine Products: